Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Subscribe To Our Newsletter & Stay Updated
